Regen BioPharma, Inc. Provides Shareholder Update on Company’s Activities and Direction

The convertible-note payoff was funded by a new promissory note, while equity funding remains subject to conditions.

Rhea-AI Summary

Regen BioPharma (RGBP) entered a common stock purchase agreement with Coventry Enterprises providing an equity financing facility of up to $10 million.

The facility runs for 36 months, subject to agreement conditions and an effective registration statement. Regen also paid off two convertible notes totaling approximately $60,000, funded by a new promissory note issued to Coventry. The company is pursuing joint ventures involving artificial intelligence modeling for clinical trials and anticipates signing a nonbinding letter of intent shortly.

Regen reported apparent compromises of its website and X account, with the latter impairing social media updates. A developer is creating a replacement website, and the company is working to restore its X access.

3 points · 2 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

2 major · 5 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Up to $10,000,000 equity facility commits Coventry to purchase common shares over 36 months, subject to conditions. 60× market cap
• Major pointTwo convertible notes totaling approximately $60,000 have been paid off. 36% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Joint ventures are being pursued for research programs using artificial intelligence modeling for clinical trials.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.Common share issuance under the Coventry equity facility would dilute existing holders.
• Major pointNew promissory note issued to Coventry funded the convertible-note payoff, adding a debt obligation.
• Moderate pointNonbinding letter of intent for the joint ventures is anticipated shortly, not yet signed.
• Minor point. Forward-looking: it has not happened yet and may not happen.Equity funding depends on agreement conditions and an effective registration statement.
• Minor pointApparent website and X account compromises prompted rebuilding work and impaired social media updates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) Update on Regen’s recent activities (i.e.: debt payoff, financing, potential joint ventures): 

1. The Company has recently paid off 2 outstanding convertible notes totaling approximately $60,000. The payoff was funded with proceeds obtained through the issuance of a promissory note to Coventry Enterprises LLC.
2. The Company entered into a common stock purchase agreement with Coventry Enterprises LLC providing for an equity financing facility. This Equity Line Agreement provides that, upon the terms and subject to the conditions in the Equity Line Agreement and pursuant to an effective Registration Statement, Coventry is committed to purchase up to Ten Million Dollars ($10,000,000) of shares of common stock over the 36-month term of the Equity Line Agreement.
3. The Company is pursuing joint ventures relating to research programs utilizing artificial intelligence modeling for clinical trials. It is anticipated that a nonbinding Letter of Intent will be signed shortly.
4. The Company’s website appears to have been hacked. A website developer has been retained and is in the process of creating a new website for the Company. It also appears as if Regan’s X account has been hacked, impairing our ability to circulate news and updates through social media. The Company is working on remedying this problem. The contact information card on the Company’s current website is now working. If you have any questions or comments feel free to utilize the contact information card.
5. The Company’s CEO anticipates presenting at the Emerging Markets conference in the near future so that shareholders can be updated in real time.
   
   

About Regen BioPharma, Inc.

Regen BioPharma, Inc. is a publicly traded biotechnology company (OTC ID: RGBP) and (OTC ID: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION:

Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
Email: david.koos@regenbiopharmainc.com or
 david.koos@regenbiopharma.com
X (formerly twitter): https: //x.com/TheRegenBio

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much financing can Regen BioPharma access through the Coventry equity agreement?

Coventry is committed to purchase up to $10,000,000 of Regen common stock over the agreement’s 36-month term. Purchases are subject to the agreement’s terms and conditions and an effective registration statement.

How did Regen BioPharma fund its convertible-note payoff?

Regen funded the payoff with proceeds from a promissory note issued to Coventry Enterprises. The completed payoff covered two outstanding convertible notes totaling approximately $60,000.